Inflammatory Bowel Disease Treatment Market Size, Share & Industry Analysis, By Disease Indication (Ulcerative Colitis and Crohn’s Disease), By Route of Administration (Oral and Injectables), By Drug Class (IL Inhibitors, TNF Inhibitors, Anti-integrin, JAK Inhibitors, Corticosteroids, ASA Drugs, and Others), By Distribution Channel (Hospital Pharmacy and Retail Pharmacy & Other), and Regional Forecast, 2024-2032

The global inflammatory bowel disease treatment market size was valued at USD 26.55 billion in 2023 and is projected to grow from USD 29.57 billion in 2024 to USD 44.08 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period (2024-2032). Globally, the prevalence of ulcerative colitis and Crohn's disease is increasing due to factors, such as lifestyle changes in the people, environmental factors, and others. For instance, according to an article published by the Indian Journal of Gastroenterology in 2023, one of the significant global health concerns is inflammatory bowel disease (IBD), which affects more than  0.3% of the global population. Additionally, with the increasing emphasis on the early diagnosis of the disease, a higher diagnosis rate of the disease, and adequate reimbursement policies in developed countries supports the growth of the market. This led to the rising number of patients undergoing treatment for IBD and increased the demand for inflammatory bowel disease treatment drugs, such as TNF inhibitors, IL inhibitors, JAK inhibitors, and others in the market.

The growing awareness about the benefits of drugs such as biologics, corticosteroids, and others is increasing the adoption of inflammatory bowel disease therapeutics globally. For instance, according to the research study conducted by Science Direct, in South America, from the total 655 patients studied, biological therapy was used by 36.4% of the patients suffering from Crohn’s disease and 9.1% of the patients suffering from ulcerative colitis.

The impact of COVID-19 resulted in slower growth of the inflammatory bowel disease treatment market during the forecast period.  Several factors were responsible for the slower treatment rate of the disease, including the closure of diagnostic centres, travel restrictions, and lockdowns in many countries globally. However, in 2021, the regulations imposed by governments were relaxed, and as a result, visits to hospitals and diagnostic centers increased. The demand for inflammatory bowel disease therapeutics is projected to grow steadily during the forecast period as key market players emphasize getting regulatory approvals for their products to expand the therapeutic measures for treating this disease.

Inflammatory Bowel Disease Treatment Market Trends

Strong Focus on R&D for Treatment of Inflammatory Bowel Disease to Augment Market Growth

Technological development, such as the use of single-cell RNA sequencing, is helping healthcare professionals in the treatment of inflammatory bowel disease. High dimensional technologies, such as single-cell RNA sequencing and mass cytometry have been performed on the intestinal specimens collected from the patients suffering from Crohn’s disease or ulcerative colitis.

Several benefits of the single-cell RNA sequencing analysis used to understand the molecular basis of the disease include the development of novel therapeutic approaches, optimizing the individual medicines, and preventing the disease.

• For instance, in August 2020, The University of California and VA San Diego Healthcare System (VASDHS) used transcriptomic and antigen receptor sequencing strategies to characterize tissue and immune cell features in individuals with or without ulcerative colitis.

Additionally, several companies and organizations are initiating clinical research activities to enhance the treatment options for these diseases. Such a scenario is expected to drive the market growth. In October 2022, Verily and the Crohn’s & Colitis Foundation, a non-profit organization, expanded strategic partnerships to build a longitudinal registry. This will accelerate research in Crohn’s disease and ulcerative colitis.

These advancements in technology provide an unusual view of immune cell networks in health and disease. They offer a personalized medicine approach to patients suffering from ulcerative colitis and Crohn’s disease.

Inflammatory Bowel Disease Treatment Market Growth Factors

Rising Prevalence of Disease is Presenting a Large Patient Pool Undergoing Treatment

There are numerous factors that are responsible for the increasing prevalence of ulcerative colitis and Crohn’s disease, which are genetic predisposition, environmental triggers, and immune system disturbance. The majority of the patients suffering from ulcerative colitis or Crohn’s disease have a family history of the disorder.

• For instance, according to the research study conducted by Hopkins Medicine, about 10-15% of the patients suffering from Crohn’s disease have a family history of the disorder. Approximately 5-7% of the patients suffering from ulcerative colitis have a family history of the disorder.

Various government organizations are creating awareness about these diseases in the people by educating them about the symptoms, diagnosis, and treatments available for these conditions. Thus, the rising awareness about the availability of various options of inflammatory bowel disease therapeutics and the increasing rate of disease diagnosis in developing countries are anticipated to support the market growth over the projected period.

Thus, the above-mentioned factors are leading to increasing demand for inflammatory bowel disease therapeutics.

Strong Portfolio of Pipeline Molecules to Increase Product Launches during the Forecast Period

The rising prevalence of Crohn’s disease and ulcerative colitis and the increasing awareness of the disease globally are some of the factors responsible for the inflammatory bowel disease treatment market growth. Thus, various key industry players are focusing on R&D and exploring new potential candidates for the IBD treatment.

• For instance, according to ClinicalTrials.gov, more than 145 clinical studies are active for ulcerative colitis and Crohn’s disease. The majority of the molecules are in phases 3 & 4 of the clinical trials.


• In December 2022, Roivant Sciences formed a new Vant to develop and commercialize PF-06480605 (now RVT-3101). RVT-3101 is a fully human monoclonal antibody targeting TL1A, which is currently in Phase 2b development in ulcerative colitis (UC). The Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A-directed antibody, which recently entered Phase 1.

Eli Lilly and Company used mirikizumab drug in phase 3 of clinical trials to evaluate the long-term efficacy and safety of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn's disease.

Additionally, the increasing demand for biologics for treating these conditions has influenced market players to expand their portfolios and commercialize their drugs globally. Thus, the rising regulatory approvals for the drugs launched by the key players and increasing patients' preferences for the medications are projected to support the adoption of inflammatory bowel disease therapeutics during the forecast period.

RESTRAINING FACTORS

High Cost of Drugs and Limited Reimbursement Policies to Restrict Market Growth

There is a lack of awareness about inflammatory bowel disease in developing countries, reducing the number of patients undergoing treatment. Additionally, high treatment cost, including the drug cost and other cost, is projected to limit the adoption of inflammatory bowel disease therapeutics in patients in the coming years.

• According to a study published by the BMC Gastroenterology in 2023, the annual mean cost per patient for UC and CD were between USD 6217– USD 11,477, and USD 11,034–USD 18,932, respectively, in the U.S.

Additionally, the adoption of biologics is increasing to treat ulcerative colitis and Crohn’s disease, but the high costs associated with biologics treatment are limiting the market growth.

• For instance, according to the National Center for Biotechnology Information (NCBI), the average annual cost of Adalimumab per person is about USD 12,343 in the U.K.

In emerging countries, such as India, China, and Russia, there is a lack of reimbursement for IBD treatment, limiting the adoption of these drugs in the region. Thus, the high cost of medications for treating inflammatory bowel disease and the lack of reimbursement policies in developing countries are restricting the demand for inflammatory bowel disease therapeutics.

Inflammatory Bowel Disease Treatment Market Segmentation Analysis

By Disease Indication Analysis

Increasing Prevalence of Crohn’s Disease to Dominate Segment Growth

On the basis of disease indication, the market is segmented into Crohn's disease and ulcerative colitis.

The Crohn’s disease segment is expected to hold a major inflammatory bowel disease treatment market share over the forecast period. The growth of this segment is attributed to the increasing prevalence of Crohn’s disease and the number of patients undergoing treatment for Crohn’s disease globally. For instance, according to the Deutsches Ärzteblatt, the prevalence of Crohn’s disease in Germany is approximately 100 to 200 per 100,000 people.

The growth of the ulcerative colitis segment is attributed to increasing drug approvals by regulatory authorities for the treatment of ulcerative colitis and the increasing treatment rate of the disease globally.

• For instance, in October 2023, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for VELSIPITY (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).


• In March 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) approval for the drug RINVOQ (upadacitinib) for treating adults with moderate to severely active ulcerative colitis.

By Route of Administration Analysis

Injectables Segment to Hold Largest Market Share due to Rapid Adoption of Biologics

By route of administration, the global market is divided into oral and injectables.

The injectables segment is anticipated to hold largest market share due to factors such as increasing adoption of biologics for the treatment of ulcerative colitis & Crohn’s disease and increasing product approvals for biologics. For instance, in February 2021, AbbVie Inc. announced the FDA approval of HUMIRA to treat moderate to severely active ulcerative colitis in pediatric patients. HUMIRA is administered through subcutaneous injections. Thus, the increasing demand for biologics for IBD treatment supports the growth of the injectables segment.

The growth of the oral segment is attributed to the easy availability of oral drugs for treating IBD and the convenience of self-administration of oral drugs for treating mild to moderate ulcerative colitis and Crohn’s disease.

By Drug Class Analysis

TNF Inhibitors Segment Dominated Market due to Rise in their Development by Key Market Players

In terms of drug class, the market of inflammatory bowel disease therapeutics is categorized into IL Inhibitors, TNF inhibitors, anti-integrin, JAK Inhibitors, corticosteroids, ASA drugs, and others.

The TNF inhibitors segment held the leading share of the market. Monoclonal antibodies are used for targeting to induce and maintain remission in patients with inflammatory bowel disease, which supports the segment’s growth in the market. Additionally, the focus of the key market players on developing TNF inhibitors is responsible for the segment's dominance.

• For instance, Celltrion is conducting a phase-3 trial for its CT-P13 SC (Infliximab) – a TNF inhibitor, to evaluate its potential for treating moderate to severe Crohn's disease. Thus, the strong portfolio of pharmaceutical companies & pipeline of TNF inhibitors for the treatment of inflammatory bowel disease is anticipated to drive the growth of the segment.

The JAK inhibitors segment held a significant market share owing to increasing product approvals for JAK inhibitors, the oral route of administration, and the rapid onset of action.

By Distribution Channel Analysis

Hospital Pharmacy Segment Held Significant Market Share due to Reimbursement Policies in Developing Countries

In terms of distribution channel, the market is segmented into hospital pharmacy and retail pharmacy & other.

The hospital pharmacy segment dominated the market with a significant share owing to reimbursement policies in developing countries, which cover the high cost of these drugs. For instance, according to Baylor Scott & White, in the U.S., approximately 45.0% of the costs are covered for the pharmacy, including injectable drugs and others.

The growth of retail pharmacy & other segment is attributed to the increasing demand for the drugs, such as JAK inhibitors, a corticosteroid that is easily available in retail pharmacies. Also, globally, the increasing adoption of online pharmacies is supporting the growth of the segment.

REGIONAL INSIGHTS

The market size in North America stood at USD 10.89 billion in 2023, which was driven by the higher adoption of biologics for the treatment of ulcerative colitis and Crohn’s disease, favorable reimbursement policies for the treatment, and increasing prevalence of these diseases in the U.S. and Canada. For instance, according to the National Center for Biotechnology Information (NCBI), the prevalence of inflammatory bowel disease in Canada will be over 0.75% in 2021.

Similarly, strategic activities by key companies are expected to propel regional growth. In April 2023, Merck and Prometheus Biosciences, Inc. entered into a definitive agreement under which Merck acquired Prometheus for USD 200.00 per share in cash for a total equity value of approximately USD 10.8 billion. This initiative would enhance the company's immunology pipeline.

Europe held the second-largest share of the market in 2021. The major factors driving the market growth include the increasing treatment population of the disease in the region. Different treatment options available for the disease are some factors driving the market growth in Europe.

The market in the Asia Pacific will exhibit a higher CAGR over the forecast period owing to increasing awareness about ulcerative colitis and Crohn’s disease in the region and increasing approvals for the drugs to treat these diseases. For instance, in March 2022, EA Pharma Co., Ltd. received approval in Japan for CAROGRA indicated to treat ulcerative colitis.

The market in Latin America is growing due to the increasing prevalence of Crohn’s disease and ulcerative colitis, availability of different treatment options, increased healthcare spending, and rising awareness about these conditions in the region.

The Middle East & Africa market will continue to expand at a considerable market share during the forecast period attributable to people's lifestyle changes and the increasing prevalence of smoking, contributing to the rising prevalence of the disease. Additionally, the number of people seeking the treatment of these diseases is increasing, driving the region's market growth.

List of Key Companies in Inflammatory Bowel Disease Treatment Market

AbbVie Inc. Leads the Market with its Strong Portfolio of Drugs

The market is consolidated, with a few key companies holding a major share of the market. Industry leader AbbVie Inc. holds a dominating place with strong portfolio biologic drugs for the treatment of ulcerative colitis and Crohn’s disease. Successful penetration across major geographies made the company a leading player globally. Takeda Pharmaceutical Company Limited, CELGENE CORPORATION, and Johnson & Johnson Services, Inc. are some of the major players in the market. New product launches and mergers & acquisitions by these key market players are supporting the dominance of these players in the market.

• For instance, in October 2021, Bristol-Myers Squibb Company announced the approval of Zeposia (ozanimod) by the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).


• In May 2023, CELLTRION INC. received U.S. FDA approval for Yuflyma (adalimumab-aaty) biosimilar for 8 indications, including Crohn’s disease and ulcerative colitis.

LIST OF KEY PLAYERS PROFILED:

• AbbVie Inc. (U.S.)


• Takeda Pharmaceutical Company Limited (Tokyo)


• UCB S.A. (Belgium)


• Bausch Health Companies Inc. (Canada)


• Bristol-Myers Squibb Company (U.S.)


• Pfizer Inc. (U.S.)


• CELLTRION INC. (South Korea)


• Johnson & Johnson Services, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• February 2024: Pfizer Inc. received a European Commission (EC) grant for the marketing authorization of VELSIPITY (etrasimod) in the European Union. It is used in the treatment of patients aged 16 years and older with moderately to severely active ulcerative colitis (UC).


• October 2023: Sanofi and Teva Pharmaceuticals collaborated to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.


• May 2023, AbbVie Inc. received approval from the U.S. FDA for RINVOQ (upadacitinib) to treat moderately to severely active Crohn’s disease.


• April 2023, AbbVie Inc. received approval from the European Commission for RINVOQ to treat moderately to severely active Crohn’s disease.


• February 2023, Eli Lilly and Janssen Pharmaceuticals collaborated to overcome the obstacles associated with pediatric drug studies for Crohn’s disease and accelerate the evaluation process.


• March 2022, AbbVie Inc. received the U.S. Food and Drug Administration (FDA) approval for RINVOQ (upadacitinib) for the treatment of adults with moderate to severe Ulcerative Colitis (UC).


• May 2021, Bristol-Myers Squibb Company received the U.S. Food and Drug Administration (FDA) approval for Zeposia (ozanimod) 0.92 mg for treating adults with moderately to severely active UC.

REPORT COVERAGE

The research report provides a detailed market analysis. It focuses on key aspects such as leading companies, drug class, disease indication, and distribution channel. Besides this, it offers insights into the market trends, impact of COVID-19, and prevalence of ulcerative colitis and Crohn’s disease, among other key insights. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 5.8% from 2024 to 2032
Unit	Value (USD billion)
Segmentation	By Disease Indication Ulcerative Colitis Crohn's Disease
By Route of Administration Oral Injectables
By Drug Class IL Inhibitors TNF Inhibitors Anti-integrin JAK Inhibitors Corticosteroids ASA Drugs Others
By Distribution Channel Hospital Pharmacy Retail Pharmacy & Other
By Geography North America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country) U.S. (By Disease Indication) Canada (By Disease Indication) Europe (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country) U.K. (By Disease Indication) Germany (By Disease Indication) France (By Disease Indication) Italy (By Disease Indication) Spain (By Disease Indication) Scandinavia (By Disease Indication) Rest of Europe (By Disease Indication) Asia Pacific (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country) China (By Disease Indication) Japan (By Disease Indication) India (By Disease Indication) Australia (By Disease Indication) Southeast Asia (By Disease Indication) Rest of Asia Pacific (By Disease Indication) Latin America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country) Brazil (By Disease Indication) Mexico (By Disease Indication) Rest of Latin America (By Disease Indication) Middle East & Africa (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country) GCC (By Disease Indication) South Africa (By Disease Indication) Rest of MEA (By Disease Indication)